Navigation Links
Response Biomedical appoints S. Wayne Kay Chief Executive Officer

VANCOUVER, Sept. 12 /PRNewswire-FirstCall/ - Response Biomedical Corporation (TSX-V: RBM, OTCBB: RPBIF) today announced the appointment of S. Wayne Kay as Chief Executive Officer (CEO). Mr. Kay was also appointed to the Company's Board of Directors.

Mr. Kay is a former President, CEO and Director of Quidel Corporation, a leading global company in the discovery, development, manufacturing and marketing of rapid diagnostic solutions at the point-of-care (POC) in infectious diseases and reproductive health. During his tenure he designed and managed a strategy responsible for building and sustaining unprecedented market leadership of rapid influenza testing (from an approximately 2 percent to 49 percent market share). He was also responsible for significantly improving the financial performance of the company during his tenure. Since leaving Quidel in 2004, Mr. Kay served as an executive advisor to the management and boards of several early stage companies, mainly in the San Francisco and San Diego areas. He also served as an executive advisor to one of the US's most successful blue-chip healthcare/life sciences venture capital funds, Kleiner Perkins Caufield and Byers.

"We are very excited to have attracted such an experienced, proven executive to lead Response Biomedical," said Dr. Richard Bastiani, Chairman. "Wayne has a wealth of experience in the diagnostics industry, and particularly in POC, and has a proven acumen for building strong teams and executing on strategy. He led Quidel through a strong expansion phase in their history and his many years experience will be invaluable to lead the Company, as we begin our expected rapid growth phase."

"I am very pleased to be joining Response Biomedical at this exciting time in the evolution of the Company," said Mr. Kay. "With partnerships in place with Shionogi & Co. Ltd. and 3M Company, we are poised for strong growth. I look forward to leading the execution of our cardiovascular partnering strategy, as well as the scale-up in manufacturing, the launch of the new RAMP(R) Reader and the regulatory approval of three products, all anticipated in the next few quarters. These are the building blocks which I believe will significantly enhance shareholder value."

Dr. Bastiani continued, "On behalf of the Board of Directors, I'd also like to take this opportunity to thank Bill Radvak for his many years of dedicated service to the Company."

As part of Mr. Kay's compensation package, he has been granted options to acquire 1,500,000 common shares of the Company, subject to vesting requirements. The options are exercisable at a price of $1.07 per common share.

About Response Biomedical

Response Biomedical develops, manufactures and markets rapid on-site diagnostic tests for use with its portable RAMP Platform for clinical and environmental applications. RAMP represents a new paradigm in diagnostics that provides high sensitivity and reliable information in minutes. It is ideally suited to both point-of-care testing and laboratory use. The RAMP system consists of a portable fluorescent reader and single-use disposable test cartridges, and has the potential to be adapted to more than 250 medical and non-medical tests currently performed in laboratories. RAMP clinical tests are commercially available for the early detection of heart attack and congestive heart failure.

In late 2006, the Company formed a strategic alliance with 3M Company to commercialize rapid infectious disease tests. In the non-clinical market, RAMP Tests are currently provided for the environmental detection of West Nile Virus, and Biodefense applications including the rapid on-site detection of anthrax, smallpox, ricin and botulinum toxin. Several other product applications are under development. The Company has achieved CE Marking and its Quality Management System is registered to ISO 13485: 2003 and ISO 9001: 2000.

Response Biomedical is a publicly traded company, listed on the TSX Venture Exchange under the trading symbol "RBM" and quoted on the OTC Bulletin Board under the symbol "RPBIF". For further information, please visit the Company's website at

The TSX Venture Exchange has not reviewed and does not accept

responsibility for the adequacy or accuracy of this release.

Note on Forward-Looking Statements

Statements contained in this press release relating to future results, events or developments, for example, statements containing the words "believes," "may," "could", "plans," "will," "estimate," "continue," "anticipates," "intends," "expects", "goal" and similar expressions, are "forward-looking statements" or "forward-looking information" under applicable United States and Canadian securities laws. Forward-looking statements or information may involve, but are not limited to, comments with respect to our planned activities, business plan and strategies and their future implementation, and our expectations for our financial condition and the results of, or outlook for, our business operations generally. Forward-looking statements or information are subject to the related assumptions made by us and involve known and unknown risks, uncertainties and other factors that may cause actual results, events or developments to be materially different from those expressed or implied by such statements or information.

Many of such risks, uncertainties and other factors form part of our underlying assumptions, and include, among other things, financial risks that would affect our operations such as our available working capital and cash flows and whether and for how long available funds will be sufficient to fund our operations and our ability to raise additional capital as and when needed; our ability to establish, and our dependence upon, relationships with strategic alliance partners to develop and commercialize products; our ability to attract and retain qualified personnel; our ability to effectively and efficiently manage the planned growth of our operations; changes in business strategy or development plans; and other factors referenced in our annual report on Form 20-F and other filings with Canadian and United States securities regulatory authorities.

Given these uncertainties, assumptions and risks, readers are cautioned not to place undue reliance on such forward-looking statements or information. We disclaim any obligation to update, or to publicly announce any revisions to, any such statements or information to reflect future results, events or developments.

CONTACT: Bill Wickson, Manager, Investor Relations, Response Biomedical Corporation, Tel (604) 456-6073, Email:; Brian Korb, Vice-President, The Trout Group LLC, Tel: (646) 378-2923, Email:

SOURCE Response Biomedical Corp.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Stress response increases suicide risk
2. Gene variation simulates cholesterol response to oestrogen
3. Alcohol injures stress hormone response
4. Self control makes stress response easy
5. Perceived stress decreases vaccine response
6. Response to chemotherapy could be measured by Prostate-Specific Antigen Doubling Time
7. Harmful chemicals change the genetic response to hormone estrogen
8. Increasing Insulin Response In Type 2 Diabetics With New Protein Mixture
9. Sexes differ in response to burnout on the job and depression
10. Reflecting On Personal Values Can Lower Stress Responses
11. Chromosome Ends Trigger DNA Damage Response For Telomere Protection
Post Your Comments:
(Date:10/13/2015)... ... ... In an age where the cost of energy is rising, Susquehanna Health’s ... 2009. The Williamsport Regional Medical Center (WRMC) campus has grown 50 percent since 2010, ... , According to Facilities Management Administrative Director Dieter Reichmann, this is the result of ...
(Date:10/13/2015)... ... 2015 , ... Dr. Poneh Ghasri, dentist in West Hollywood , comments ... research, which was conducted at the Dental Institute at King's College London in the ... during pregnancy and future dental health in the child. For years, researchers have long ...
(Date:10/13/2015)... New York, NY (PRWEB) , ... October 13, 2015 , ... ... Android®. The app helps individuals find others to train with, participate in local fitness ... the App Store and Google Play. , “As high medical costs drive us to ...
(Date:10/13/2015)... ... 13, 2015 , ... Leading Internet marketing product review website ... Academy" training course . Singal's new program, in which he reveals his strategies ... the Internet are weighing in with reviews. , "Considering the fairly high number ...
(Date:10/13/2015)... ... October 13, 2015 , ... Altec Products, ... Title Sponsorship of Synergy 2015. The annual WennSoft KEY2ACT user conference will take ... and will unite customers, partners, WennSoft team members and sponsors to facilitate the ...
Breaking Medicine News(10 mins):
(Date:10/13/2015)... -- Data Science Automation (DSA), a system integration and automation engineering ... in the United Kingdom (UK) as ... . The decision to open the new office comes ... customers in the medical device industry throughout the UK. ... have had tremendous success over the last several years in ...
(Date:10/13/2015)... 13, 2015  SRI International has been awarded ... over five years by the National Institute of ... National Institutes of Health, for the development of ... effects of radiation exposure. Under this multi-year contract, ... International will provide services, facilities, expertise and capabilities ...
(Date:10/13/2015)... 2015  Nanomedical Diagnostics, a biotech company developing ... diagnostics, announces the completion of a Series A ... Ventures. --> ... monitoring and diagnostic platforms that empower individuals to ... will enable the company to commercially release AGILE ...
Breaking Medicine Technology: